87 related articles for article (PubMed ID: 21849800)
21. Renal effects of long-term leptin infusion and preventive role of losartan treatment in rats.
Gunduz Z; Dursun N; Akgun H; Ozturk F; Okur H; Koc N
Regul Pept; 2005 Dec; 132(1-3):59-66. PubMed ID: 16229907
[TBL] [Abstract][Full Text] [Related]
22. Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes.
Qin J; Zhang Z; Liu J; Sun L; Hu L; Cooper ME; Cao Z
Kidney Int; 2003 Aug; 64(2):565-71. PubMed ID: 12846751
[TBL] [Abstract][Full Text] [Related]
23. Neonatal losartan treatment suppresses renal expression of molecules involved in cell-cell and cell-matrix interactions.
Chen Y; Lasaitiene D; Gabrielsson BG; Carlsson LM; Billig H; Carlsson B; Marcussen N; Sun XF; Friberg P
J Am Soc Nephrol; 2004 May; 15(5):1232-43. PubMed ID: 15100363
[TBL] [Abstract][Full Text] [Related]
24. Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension.
Bayorh MA; Ganafa AA; Eatman D; Walton M; Feuerstein GZ
Am J Hypertens; 2005 Nov; 18(11):1496-502. PubMed ID: 16280288
[TBL] [Abstract][Full Text] [Related]
25. Effect of irbesartan on the antioxidant defence system and nitric oxide release in diabetic rat kidney.
Anjaneyulu M; Chopra K
Am J Nephrol; 2004; 24(5):488-96. PubMed ID: 15353911
[TBL] [Abstract][Full Text] [Related]
26. Diltiazem attenuates oxidative stress in diabetic rats.
Anjaneyulu M; Chopra K
Ren Fail; 2005; 27(3):335-44. PubMed ID: 15957552
[TBL] [Abstract][Full Text] [Related]
27. Oxidative stress status in kidney tissue after losartan and atenolol treatment in experimental renal failure.
Pechter U; Aunapuu M; Riispere Z; Vihalemm T; Kullissaar T; Zilmer K; Zilmer M; Ots M
Nephron Exp Nephrol; 2004; 97(2):e33-7. PubMed ID: 15218321
[TBL] [Abstract][Full Text] [Related]
28. The role of angiotensin II receptor 1 (AT1) blockade in cisplatin-induced nephrotoxicity in rats: gender-related differences.
Haghighi M; Nematbakhsh M; Talebi A; Nasri H; Ashrafi F; Roshanaei K; Eshraghi-Jazi F; Pezeshki Z; Safari T
Ren Fail; 2012; 34(8):1046-51. PubMed ID: 22780575
[TBL] [Abstract][Full Text] [Related]
29. Hyperbaric oxygen treatment augments the efficacy of a losartan regime in an experimental nephrotic syndrome model.
Yilmaz MI; Korkmaz A; Kaya A; Sonmez A; Caglar K; Topal T; Eyileten T; Yenicesu M; Acikel C; Oter S; Yaman H; Aktug H; Oguz Y; Vural A; Ikizler TA
Nephron Exp Nephrol; 2006; 104(1):e15-22. PubMed ID: 16699289
[TBL] [Abstract][Full Text] [Related]
30. Changes seen in the aging kidney and the effect of blocking the renin-angiotensin system.
Inserra F; Basso N; Ferder M; Userpater M; Stella I; Paglia N; Inserra P; Tenembaum D; Ferder L
Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):341-6. PubMed ID: 19574289
[TBL] [Abstract][Full Text] [Related]
31. Ulinastatin attenuates renal interstitial inflammation and inhibits fibrosis progression in rats under unilateral ureteral obstruction.
Jiang GT; Chen X; Li D; An HX; Jiao JD
Mol Med Rep; 2014 Sep; 10(3):1501-8. PubMed ID: 24926571
[TBL] [Abstract][Full Text] [Related]
32. Losartan exerts renoprotection through NAD(P)H oxidase downregulation in a renovascular model of hypertension.
Polizio AH; Balestrasse KB; Gornalusse GG; Gorzalczany SB; Santa-Cruz DM; Yannarelli GG; Peña C; Tomaro ML
Regul Pept; 2009 Aug; 156(1-3):28-33. PubMed ID: 19445972
[TBL] [Abstract][Full Text] [Related]
33. [Effect of losartan on the state of kidney function in rats with experimental hyperthyroidism].
Zaporozhan VN; Dolomatov SI
Eksp Klin Farmakol; 2007; 70(2):65-6. PubMed ID: 17523456
[TBL] [Abstract][Full Text] [Related]
34. Downregulation of apoptosis and modulation of TGF-β1 by sodium selenate prevents streptozotocin-induced diabetic rat renal impairment.
Roy S; Dontamalla SK; Mondru AK; Sannigrahi S; Veerareddy PR
Biol Trace Elem Res; 2011 Jan; 139(1):55-71. PubMed ID: 20174975
[TBL] [Abstract][Full Text] [Related]
35. [Effects of losartan on the levels of angiotensin II and its type-1 receptor in diabetic rat kidney].
Wu W; Ding HL; Chen LH; Fu ZZ
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Dec; 26(12):1742-4. PubMed ID: 17259110
[TBL] [Abstract][Full Text] [Related]
36. Enhanced effect of combined treatment with SMP-534 (antifibrotic agent) and losartan in diabetic nephropathy.
Sugaru E; Nakagawa T; Ono-Kishino M; Nagamine J; Tokunaga T; Kitoh M; Hume WE; Nagata R; Taiji M
Am J Nephrol; 2006; 26(1):50-8. PubMed ID: 16508247
[TBL] [Abstract][Full Text] [Related]
37. Losartan modulation on NOS isoforms and COX-2 expression in early renal fibrogenesis in unilateral obstruction.
Manucha W; Oliveros L; Carrizo L; Seltzer A; Vallés P
Kidney Int; 2004 Jun; 65(6):2091-107. PubMed ID: 15149322
[TBL] [Abstract][Full Text] [Related]
38. Hesperidin attenuates cisplatin-induced acute renal injury by decreasing oxidative stress, inflammation and DNA damage.
Sahu BD; Kuncha M; Sindhura GJ; Sistla R
Phytomedicine; 2013 Mar; 20(5):453-60. PubMed ID: 23353054
[TBL] [Abstract][Full Text] [Related]
39. Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction.
Vaziri ND; Bai Y; Ni Z; Quiroz Y; Pandian R; Rodriguez-Iturbe B
J Pharmacol Exp Ther; 2007 Oct; 323(1):85-93. PubMed ID: 17636006
[TBL] [Abstract][Full Text] [Related]
40. Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats.
Castoldi G; di Gioia CR; Bombardi C; Maestroni S; Carletti R; Steckelings UM; Dahlöf B; Unger T; Zerbini G; Stella A
Am J Physiol Renal Physiol; 2014 Nov; 307(10):F1123-31. PubMed ID: 25186297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
